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A series of analogues of cryptolepine (1) have been synthesized and evaluated for their in vitro
antiplasmodial and cytotoxic properties. The IC50 values of several compounds (11a, 11k-m,
11o, 13) against Plasmodium falciparum (strain K1) were <0.1 íM, 5-10-fold lower than that
of 1 but their cytotoxicities were only 2-4 times greater than that of 1. Compounds with a
halogen in the quinoline ring and a halogen or a nitro group in the indole ring have enhanced
antiplasmodial activity. In mice infected with P. berghei, the 7-bromo-2-chloro (11k) and
2-bromo-7-nitro (13) derivatives of 1 suppressed parasitemia by >90% at doses of 25 mg kg-1
day-1 with no apparent toxicity to the mice. 2,7-Dibromocryptolepine (15) was evaluated at
several dose levels, and a dose-dependent suppression of parasitemia was seen (ED90 ) 21.6
mg kg-1 day-1). The antimalarial mode of action of 1 appears to be similar to that of chloroquine
and involves the inhibition of hemozoin formation. A number of analogues were assessed for
their effects on the inhibition of â-hematin (hemozoin) formation, and the results were compared
with their antiplasmodial activities having taken account of their predicted accumulation into
the acidic parasite food vacuole. No correlation was seen (r2 ) 0.0781) suggesting that the
potent antimalarial activity of compounds such as 15 involves other mechanisms in addition
to the inhibition of hemozoin formation.
Introduction
Recently, the urgent need for new agents to combat
the growing problem of malaria caused by resistant
strains of Plasmodium falciparum has been highlight-
ed.1 Natural products, exemplified by quinine and arte-
misinin, have made an immense contribution to malaria
treatment and have also served as lead compounds for
the development of synthetic and semisynthetic anti-
malarials. The continued investigation of natural prod-
ucts, particularly those originating from plant species
used in traditional medicines for the treatment of ma-
laria may prove to be fruitful in the search for new drugs
to treat this disease that currently claims the lives of
up to 3 million people each year.
Cryptolepine (5-methyl-10H-indolo[3,2-b]quinoline)
(1) is an indoloquinoline alkaloid present as the major
constituent in the roots of the West African climbing
shrub Cryptolepis sanguinolenta (family Periplocaceae).
A decoction of the roots of this species is used in tra-
ditional medicine for the treatment of malaria as well
as for a number of other infectious and noninfectious
diseases.2 Cryptolepine (1) has potent in vitro antiplas-
modial activity3 but it is also cytotoxic on account of its
abilities to intercalate into DNA and inhibit topoiso-
merase II as well as DNA synthesis.4,5 However, in a
previous study,3 it was shown that the antiplasmodial
action of 1 is due, at least in part, to a chloroquine-like
action (inhibition of â-hematin formation) that does not
depend on intercalation into DNA. Chloroquine (and
related 4-aminoquinoline antimalarials) are believed to
act primarily by binding to heme released following the
digestion of hemoglobin in the host red blood cells, thus
preventing the detoxification of heme.6 Normally, heme
is detoxified by conversion into insoluble hemozoin (ma-
laria pigment) that has been shown to be a dimer of
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heme and is identical to â-hematin7 (formed when hem-
atin is incubated at 60 °C in 4.5 M acetate buffer).8 The
binding of chloroquine to heme prevents hemozoin form-
ation, and the free heme or drug-heme complex is be-
lieved to exert a toxic effect on the parasite.6 However,
this action is enhanced as a result of the accumulation
of chloroquine into the acidic food vacuole of the malaria
parasite, the site of hemoglobin digestion.6 Since 1, in
common with chloroquine, is a weak base, it is possible
that accumulation into the food vacuole and the inhibi-
tion of haemozoin formation are involved in its anti-
plasmodial mode of action.
In a previous study, the synthesis of a series of
analogues of 1 was reported, and some of these were
shown to have enhanced antiplasmodial activities in
vitro against both chloroquine-sensitive and chloro-
quine-resistant strains of P. falciparum.3 Further, sev-
eral compounds were found to have encouraging activity
in mice infected with P. berghei, and importantly, in
contrast to 1, no apparent toxicity was seen in the mice.
These results indicated that analogues of 1 have poten-
tial as lead compounds to new antimalarial agents.
In this paper we report the synthesis of a further 16
cryptolepine derivatives of which 11 are novel in order
to gain additional information with respect to structure-
activity relationships. Compounds were assessed for
their in vitro antiplasmodial activities against P. falci-
parum (multidrug-resistant strain K1) and for cytotox-
icity against MAC15A (mouse adenocarcinomas of the
colon) cells. Selected compounds were also assessed for
in vivo antimalarial activity in mice infected with P.
berghei. In addition, the pKa values and â-hematin
inhibitory activities of a series of cryptolepine analogues
were determined in an attempt to estimate the impor-
tance of the accumulation into the parasite food vacuole
and the inhibition of â-hematin formation to the anti-
plasmodial action of these compounds. Previously, it has
been shown that for a series of chloroquine analogues
there is a correlation between antiplasmodial activities
against a chloroquine-sensitive strain of P. falciparum
and â-hematin inhibitory activities, provided account is
taken of the accumulation of the compounds into the
acidic food vacuole of the parasite.6
Chemistry. The 5-bromo (6b), 6-chloro (6c), and O,N-
diacetylindoxyl derivatives were prepared using a syn-
thesis previously reported for O,N-diacetylindoxyl (6a)9
(Scheme 1), although some supplies of 6b were pur-
chased. The appropriate anthranilic acid derivative (2b,
2c) was reacted with chloroacetic acid (3) to give
phenylglycine-o-carboxylic acid derivatives (4b, 4c) that
were then N-acetylated to give 5b and 5c. Cyclization
of the latter with Ac2O in the presence of Et3N gave O,N-
diacetylindoxyl derivatives 6b and 6c.
Analogues of 1 were prepared using methodology
based on that of Holt and Petrow (1947)10 as described
previously3 (Scheme 2). O,N-Acetylindoxyl or a deriva-
tive (6a-c) was condensed with isatin (7a) or a deriva-
tive (7b-j) in the presence of KOH under anaerobic
conditions (N2) to give the corresponding quinoline-11-
carboxylic acid derivatives (8a-o). The latter were
decarboxylated by heating in diphenyl ether to give
quindoline derivatives (9a-o) which were subsequently
methylated using iodomethane in tetramethylene-
sulfone to give cryptolepine derivatives (10a-o) as their
hydroiodide salts which were then converted to their
hydrochloride salts (11a-o). Compound 13, 2-bromo-
7-nitrocryptolepine was prepared from 2-bromocryptol-
epine (12) (obtained as previously reported3) by nitration
with a mixture of nitric and glacial acetic acids (1:1)
(Scheme 3). The substitution of the nitro group at
position 7 in 13 was confirmed by NOE difference
experiments that showed a connection between the
signal for the 5-NCH3 and the singlet at ä 9.57 ppm,
(Figure 1), thus eliminating the possibility of 8-nitro
substitution. Compounds 12 and 15-18 (Figure 2) were
available from previous work.3
Results and Discussion
In Vitro Antiplasmodial Activity. Table 1 shows
the in vitro antiplasmodial and cytotoxic activities of 1
and its derivatives together with their cytotoxic/anti-
plasmodial ratios. Although the limited availability of
substituted isatin derivatives restricted the number of
cryptolepine analogues that could be made, some inter-
esting structure-activity relationships may be dis-
cerned. The 2-chloro analogue (11b) was 3-fold more
potent than 1 against P. falciparum while the 2-fluoro
analogue (11g) was 3-fold less active than 1. From
previous work,3 2-bromocryptolepine (12), (IC50 ) 0.26
íM) was of similar activity to 11b. Substitution of a
methyl or methoxy group for chlorine in position 2 (11h,
11i) resulted in a decrease in antiplasmodial activity
compared to 11b, but 3-methylcryptolepine (11j) was
3-fold more active than the 3-chloro analogue (11d).
In the case of the monochlorinated analogues, 11b
was the most potent, 3-chloro derivative 11d was 3-
fold less potent, and 4-chlorocryptolepine (11e) was
found to be 28-fold less active than 11b. The 8-chloro
analogue (11f) was at least 6-fold less active than 11b
(1 íM was the highest concentration tested). In the case
of dichloro substitution, 11a (1,2-dichloro) was 2-fold
more active than 11b (2-chloro) while the activity of 2,3-
dichlorocryptolepine (11c) was midway between that of
11b and 11d. It would be of interest to prepare 1-chlo-
rocryptolepine to establish whether this is more potent
than 11a and 11b, as there appears to be a trend for
higher activity from position 4 to position 1 for chloro
analogues.
In a previous study3 it was shown that 2,7-dibromo-
cryptolepine (15) was 5-fold more active against plasmo-
Scheme 1a
a Reagents and conditions: (i) Na2CO3; (ii) Ac2O, Na2CO3; (iii)
Ac2O, Et3N, reflux.
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dia than either the 2-bromo (12), or 7-bromo (14)
analogues, and therefore in this study several similar
7-brominated compounds (11k-n) were prepared. Com-
pounds 11k-m showed antiplasmodial activities at
least 5-fold greater than their monohalogenated ana-
logues 11b, 11g, and 11d, respectively. However, 7-bro-
mo-3-methylcryptolepine (11n) was only about half as
potent as 3-methyl analogue (11j), further supporting
the above observation that alkylation appears to be
detrimental for antiplasmodial activity. The 2,8-dichlo-
rinated compound 11o was similarly potent as 11k
showing that 7-bromo substitution may be replaced with
8-chloro substitution without loss of activity. Similarly,
replacement of the 7-bromo substituent with a nitro
Scheme 2a
a Reagents and conditions: (i) KOH, N2, reflux; (ii) Ph2O, 250 °C; (iii) CH3I, tetramethylene sulfone, 50 °C; (iv) NH4OH, HCl.
Scheme 3a
a Reagents and conditions: (i) HNO3: HOAc 1: 1, room temp.
Figure 1. NOE connections from the N-CH3 in 13.
Figure 2. Structures 12 and 14-18.
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group as in 13 retained antiplasmodial activity similar
to that of 2,7-dibromocryptolepine (15, IC50 ) 0.05 íM).3
In Vitro Cytotoxicity. For all of the compounds
except for 11e, the cytotoxic/antiplasmodial ratios were
>1 (Table 1), indicating some selectivity against plas-
modia even though a long cell-drug exposure time (96
h), was used in the cytotoxicity test. Although the most
potent antiplasmodial compounds 11a, 11k-m, 11o,
and 13 were all 2 to 4-fold more cytotoxic than 1, their
selectivity ratios were all >10, the most selective being
11k and 11m (selectivity ratios 57.7 and 30.8, respec-
tively). However, in vitro cytotoxicity did not parallel
toxicity in vivo, as 11k and 13 were not toxic to mice
despite having greater in vitro cytotoxicity than 1,
whereas 11i that had similar cytototoxicity to 1 did
exhibit toxicity in mice.
In Vivo Antimalarial Activity. Selected compounds
were assessed for antimalarial activity against P.
berghei in mice using Peters’s 4-day suppressive test in
which activity is determined by comparing parasitemias
of animals treated for 4 days with those of untreated
controls on day 5.11 Observation of the mice was then
continued in order to record their survival times (taken
as the number of days before illness due to malaria
became apparent). In previous work3 it was shown that
1 is toxic to mice after 2 doses of 20 mg kg-1, but some
analogues, notably 2,7-dibromocryptolepine (15), was
not toxic at a dose of 12.5 mg kg-1 for 4 days and
suppressed parasitemia by 89%. Here we report further
experiments in which four dose levels of 15 were used
to examine the dose-response relationship. As shown
in Table 2, a clear dose-dependent response was seen
with doses ranging from 3.125 to 25 mg kg-1 day-1, and
the ED50 and ED90 values were 6.92 and 21.46 mg kg-1
day-1, respectively. At the highest dose (25 mg kg-1
day-1) parasitemia was suppressed by 91.4%, there was
no apparent toxicity, and the mice survived 5 days
longer than the untreated controls. Similar results in
terms of both suppression of parasitemia and survival
were obtained with 11k and with 13 with no apparent
toxicity to the mice, but the 2,8-dichloro analogue 11o
showed signs of toxicity after the second dose, so that
no further doses were administered. Compounds 11g
and 11i were less active against P. berghei in vivo, which
was consistent with their relatively weak antiplasmo-
dial activities in vitro.
Correlation of Antiplasmodial Activities with
Ability To Inhibit â-Hematin Formation. To predict
the accumulation of cryptolepine derivatives into the
acidic parasite food vacuole, pKa values for a number
Table 1. In Vitro Antiplasmodial Activities of Cryptolepine Derivatives and Chloroquine Diphosphate and Cytotoxic Activities of
Cryptolepine Derivatives Against MAC 15A Cells
compounda activity vs P. falciparum in vitrob activity vs MAC 15a cellsb cytotoxic/antiplasmodial ratio
1, cryptolepine 0.440 ( 0.22 3.95 ( 1.10 8.98
11a, 1,2-dichlorocryptolepine 0.088 ( 0.005 1.91 ( 0.35 21.7
11b, 2-chlorocryptolepine 0.166 ( 0.004 2.24 ( 0.35 13.5
11c, 2,3-dichlorocryptolepine 0.356 ( 0.008 3.32 ( 1.24 9.33
11d, 3-chlorocryptolepine 0.448 ( 0.009 1.75 ( 0.38 3.90
11e, 4-chlorocryptolepine 4.69 ( 0.23 3.54 ( 0.93 0.76
11f, 8-chlorocryptolepine >1 8.15 ( 3.44 <8.15
11g, 2-fluorocryptolepine 1.21 ( 0.05 4.79 ( 2.21 3.96
11h, 2-methylcryptolepine 0.419 ( 0.016 4.11 ( 0.82 9.81
11i, 2-methoxycryptolepine 0.95c 4.31 ( 2.48 4.54
11j, 3-methylcryptolepine 0.149 ( 0.012 3.51 ( 0.55 23.6
11k, 7-bromo-2-chlorocryptolepine 0.030 ( 0.002 1.73 ( 0.12 57.7
11l, 7-bromo-2-fluorocryptolepine 0.063 ( 0.006 1.35 ( 0.07 21.4
11m, 7-bromo-3-chlorocryptolepine 0.037 ( 0.005 1.14 ( 0.19 30.8
11n, 7-bromo-3-methylcryptolepine 0.26c 5.21 ( 0.91 20.0
11o, 2,8-dichlorocryptolepine 0.045c 1.12 ( 0.27 24.9
13, 2-bromo-7-nitrocryptolepine 0.07 ( 0.01 1.03 ( 0.35 14.7
15, 2,7-dibromocryptolepined 0.049 ( 0.017 6.04 ( 0.49 123
chloroquine diphosphate 0.246 ( 0.013 NTe -
a Tested as hydrochloride salt unless stated otherwise. b IC50, íM ( SD; results of three separate determinations. c Mean of two
determinations. d Results from ref 3. e NT, not tested.

















1, cryptolepineb 20 c c c c
11g, 2-fluorocryptolepine 50 5.98 ( 1.91 55.1 5.0 ( 0 5.0 ( 0
11i, 2-methoxycryptolepine 50d 12.08 ( 2.93 9.3 5.0 ( 0 5.0 ( 0
15, 2,7-dibromocryptolepine 3.125 12.10 ( 1.27 15.9 10.0 ( 0 10.0 ( 0
15 6.25 7.67 ( 0.96 46.7 10.0 ( 0 11.6 ( 0.55
15 12.5 3.55 ( 0.69 75.4 10.0 ( 0 11.8 ( 0.45
15 25.0 1.24 ( 1.01 91.4 10.0 ( 0 15.0 ( 0
11k, 7-bromo-2-chlorocryptolepine 25.0 0.97 ( 0.98 91.85 11.8 ( 0.45 15.4 ( 0.89
11o, 2,8-dichlorocryptolepine 25e 9.22 ( 2.81 17.8 9.6 (0.89 14.0 ( 0
13, 2-bromo-7-nitrocryptolepine 25f 1.34 ( 0.3 90.75 6.4 ( 1.34 13.0 ( 0
chloroquine diphosphate 10 0.00 100.0 8.56 g
a Tested as hydrochloride salt unless otherwise stated. b Results from ref 3. c Toxic after the 2nd dose. d Last dose not given due to
toxicity. e Toxic after two doses; no further doses given. f Mice appeared to suffer pain and/or irritation for a few minutes after injection.
g Mice survived test.
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of derivatives were measured, and these were found to
range from 11.8 for 1 down to 6.4 for 18 (Table 3). For
all of the compounds examined, the UV spectra recorded
in buffers at different pH values showed only one
isosbestic point, indicating that only one protonable
nitrogen atom is present, and these data are consistent
with the 1H NMR spectra of 1 and its derivatives in
which the signals for the 5-N methyl groups have a
chemical shift (ä) of 5 ppm typical of quaternary
N-methyl groups so that N-10 is the only basic nitro-
gen.3 The extent of pH trapping of each of the com-
pounds into the acidic parasite food vacuole was calcu-
lated from their pKa values using eq 1 below6 except
that the right-hand top and bottom terms were omitted,
as these are applicable only for compounds such as
chloroquine that have two protonable nitrogen atoms.
In eq 1, [Q]v and [Q]e represent the vacuolar and
external drug concentrations and [H+]v and [H+]e rep-
resent the vacuolar and external hydrogen ion concen-
trations, respectively. The vacuolar and the external pH
values were taken to be 5.5 and 7.4, respectively.6 The
calculated accumulation ratios are shown in Table 3,
and the accumulation ratios relative to 1 (R) are also
given. By multiplying the values for R with the experi-
mentally obtained antiplasmodial IC50 values for each
compound, the normalized IC50 values (IC50  R) are
obtained; i.e., the IC50 values theoretically expected if
the compounds accumulated in the vacuole to the same
extent as cryptolepine. Having adjusted for the dif-
ferential accumulation of the compounds, comparison
of the normalized antiplasmodial IC50 values with the
IC50 values for the inhibition of â-hematin formation
should indicate whether a clear correlation exists be-
tween their antiplasmodial activities and their abilities
to inhibit â-hematin formation.
As shown in Table 3, the concentration of 1 in the
acidic food vacuole of the parasite is predicted to be 79.4-
fold higher than that in the extracellular fluid. Com-
pounds with pKa values of 9.1 or above (11i, 11g, 12,
15, 17), are expected to achieve similar vacuolar con-
centrations to 1, and hence their normalized IC50 values
(IC50  R) are almost identical to their experimental
antiplasmodial IC50 values. In contrast, the predicted
accumulations (R) of 16 and 18 relative to 1 are 0.48
and 0.01, respectively, so that their normalized IC50
values are smaller than the corresponding experimental
values. The quantities of the compounds required to
inhibit the formation of â-hematin by 50% (BHIA50
values) ranged from 0.63 to 1.96 equiv of drug relative
to hematin, the value for 1 (1.64) being close to that for
chloroquine diphosphate (1.44). A plot of log IC50  R
against log BHIA50 values (Figure 3) shows that there
is no correlation at all between the normalized IC50
values and the ability of compounds to inhibit â-hematin
formation (r2 ) 0.0781). Kaschula et al.6 reported that
a direct proportionality between antiplasmodial activity
normalized for pH trapping and â-hematin inhibitory
activity was observed with a series of 4-aminoquinolines
using a chloroquine-sensitive strain of P. falciparum
(D10). In this study a chloroquine-resistant strain of P.
falciparum (K1) was used, but it has been shown
previously that there was no cross-resistance between
a series of analogues of 1 and chloroquine3 so that
resistance mechanisms such as enhanced efflux of drug
from the parasite food vacuole that may occur in
chloroquine-resistant parasites12 are unlikely to have
affected the vacuolar accumulation of the compounds
investigated in this study.
Table 3. Relationship between pKa, Normalized Antiplasmodial IC50 Values, and Inhibition of â-Hematin Formation for 1, Some
Analogues of 1, and Chloroquine Diphosphate
compounda IC50b pKac acc. ratiod Re IC50  Rf BHIA50g
1, cryptolepine sulfate 0.44 ( 0.22 11.8 79.43 1.00 0.44 1.64 ( 0.007
11i, 2-methoxycryptolepine 0.95 11.45 79.42 1.00 0.95 1.96 ( 0.89
11g, 2-fluorocryptolepine 1.21 ( 0.05 11.25 79.41 1.00 1.21 1.24 ( 0.43
12, 2-bromocryptolepine 0.26 ( 0.09 10.2 79.30 1.00 0.26 0.63 ( 0.10
17, 9-nitrocryptolepine 6.92 ( 1.89 9.60 78.94 0.99 6.85 0.84 ( 0.001
15, 2,7-dibromocryptolepine 0.049 ( 0.017 9.10 77.90 0.99 0.049 1.53 ( 0.28
16, 8,11-dichlorocryptolepine 27.0 ( 5.4 7.35 37.94 0.48 12.91 0.96h
18, 7,9-dinitrocryptolepine 0.65 ( 0.21 6.40 0.813 0.01 0.0065 0.92 ( 0.19
chloroquine diphosphate 0.18 ( 0.02 8.55, 9.81i 5896j 74.2j 13.36j 1.44 ( 0.16
a Tested as hydrochloride salts except where otherwise stated. b From ref 3; antiplasmodial activity against P. falciparum (K1), IC50,
íM ( SD; mean of not less than three separate determinations except for 11i which is the mean of two determinations. c Mean of two
determinations; all duplicates were within (0.1 of the mean value. d Vacuolar accumulation ratio calculated using eq 1 and assuming a
vacuolar pH of 5.5 and external pH of 7.4.8 e Accumulation ratio relative to cryptolepine. f Normalized IC50. g â-Hematin inhibitory activity
in equivalents of drug relative to hematin causing 50% inhibition; mean of two determinations ( SD. h Incompletely soluble; result of one




{1 + [H+]vKa2 + [H+]v2Ka1Ka2}{1 + [H+]eKa2 + [H+]e2Ka1Ka2} (1)
Figure 3. Plot of the log of the normalized antiplasmodial
IC50 (IC50 x R) versus the log of the activity against the
inhibition of â-haematin formation for 1, and some analogues
of 1 (Table 3). No correlation is seen; r2 ) 0.0781. Error bars
represent 1 SEM; in the calculation of errors for IC50  R, pKa
errors have been ignored, as these are very small compared
to those for the antiplasmodial values.
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The most potent antiplasmodial compound, 15, is
9-fold more active than 1 against plasmodia, but its
relative accumulation and its effect on â-hematin for-
mation are nearly identical to that of 1, suggesting that
the increased antiplasmodial potency of this analogue
is due neither to better accumulation nor to enhanced
activity against â-hematin formation. Conversely, the
accumulation of 18 into the parasite food vacuole is only
about 1% of that of 1 so that a very low normalized IC50
value (0.0065 íM) results, but the activity of 18 on
â-hematin formation is only 50% greater than that of
1. These results suggest that the antiplasmodial mode
of action of 1 and its analogues is only partially due to
the inhibition of hemozoin formation. In the case of 1,
it is likely that the latter action is complemented by
effects resulting from the intercalation of 1 into DNA
and possibly effects on parasite topoisomerase II, as
similar effects appear to be related to the toxicity of 1
to mammalian cells5 and in one study using fluorescence
microscopy it was reported that 1 was localized in the
parasite to a structure that may correspond to the
nucleus.13 However, this may not be the case with 12,
15, 17, and 18, as these analogues were shown to have
less ability to intercalate into DNA than 1 as judged
from their effects on the melting point (¢Tm values) of
DNA.3 Nevertheless, surprisingly the latter analogues
were not less cytotoxic than 1 against mouse adenocar-
cinoma (MAC15A) cells, although in contrast to 1 they
were not toxic to mice when assessed for antimalarial
activity in vivo.3 Analogue 15 is markedly more potent
than 1 against malaria parasites in vitro and has
encouraging in vivo activity in mice infected with P.
berghei (Table 2) which suggests that a selective anti-
plasmodial mechanism in addition to the inhibition of
hemozoin formation is operating. Further work to
investigate this would be worthwhile and may lead to
the design of more effective antimalarial analogues of
1.
While the inhibitory activities of analogues of 1 and
of chloroquine against the formation of â-hematin are
of the same order, the accumulation ratio of chloroquine
into the parasite food vacuole as predicted by eq 1
(taking the pKa values to be 8.55 and 9.816) is 5896,
more than 70-fold greater than that for 1 (79.4) although
the accumulation of chloroquine in chloroquine-resistant
parasites may be compromised by increased efflux.12
This large difference in accumulation between 1 and
chloroquine results because 1 has only one basic (pro-
tonable) nitrogen whereas chloroquine has two. It is
possible that the association of 1 with hemin would in
itself lead to an accumulation of drug into the parasite
food vacuole independently of a pH trapping mecha-
nism, but studies with chloroquine have shown that at
concentrations in the region of the IC50 of chloroquine,
negligible association with hemin would occur in the
absence of pH trapping because the affinity of chloro-
quine for hematin is too weak.6 For aminoquinolines,
affinity for hematin correlates with their abilities to
inhibit â-hematin formation, and as the latter activities
for 1 and its analogues are comparable to that of
chloroquine (Table 3), it is unlikely that 1 and its
derivatives will have sufficient affinity for heme to drive
their accumulation in the food vacuole in the absence
of another mechanism. If pH trapping is important for
the antiplasmodial action of 1 and its analogues, then
the addition of another protonable nitrogen to the
molecule may be expected to lead to an increase in
potency. The synthesis of such analogues, for example
related to 15, is currently in progress.
Conclusion
Six of the 16 analogues of 1 (11a, 11k, 11l, 11m, 11o,
13), were found to have potent in vitro antiplasmodial
activities with IC50 values <0.1 íM. The presence of a
halogen or nitro group in position 7 in addition to a
halogen substituent in the quinoline ring were found
to be beneficial for activity while alkyl or alkoxy
substitution in the ring was detrimental. A comparison
of chlorinated analogues showed that the position of
substitution in the quinoline ring substantially affected
antiplasmodial activity, with substitution in positions
1 and 2 being most favorable, but their cytototoxic
activities did not follow this trend.
Two novel compounds, 11k and 13 were shown to
have encouraging antimalarial activities in vivo with
suppression of parasitemias >90% and increased sur-
vival of animals without any apparent toxicity to the
mice even though they were more cytotoxic than 1 in
vitro. Compound 15, available from previous work3 was
found to produce a dose-dependent decrease in parasi-
taemia and increased survival compared to untreated
malaria-infected mice.
Experiments designed to explore the mode of action
of 1 indicated that there is no correlation between the
inhibition of â-hematin formation and the antiplasmo-
dial activity of analogues of 1 even when account is
taken of the predicted accumulation of the compounds
into the acidic food vacuole of the parasite by pH
trapping. The data suggests that especially for 15 there
is likely to be another mechanism(s) operating in
addition to the inhibition of hemozoin formation that
may account for the potent and selective antiplasmodial
activity of this compound.
This study supports the continued synthesis and
investigation of derivatives of 1 in the search for new
antimalarial agents.
Experimental Section
Chemistry. Isatin derivatives 7b-j were made available
to us (see acknowledgments), but some notes on their synthesis
are given below for completeness. All other chemicals were
purchased from Sigma-Aldrich Chemical Co. Ltd., Poole, U.K.
1H NMR spectra were acquired on a JEOL GX270 FT NMR
spectrometer at 270 MHz. NOE experiments on 13 were
carried out in DMSO-d6 at 25 °C on a JEOL ECA 600 NMR
spectrometer at 600 MHz. Mass spectra were run on an AEI
MS902 spectrometer equipped with an MSS data acquisition
system, version 10 (Mass Spectrometer Services, Manchester,
U.K.). C, H, and N analyses were carried out by the Chemical
and Materials Analysis Unit, University of Newcastle, U.K.,
on a Carlo Erba 1106 elemental analyzer.
Note on the Synthesis of the Isatin Derivatives Used
in This Study. Compounds 7b-j were prepared by the
Sandmeyer method14,15 by condensation of a substituted aniline
with chloral hydrate and hydroxylamine to form the corre-
sponding isonitrosoacetanilide using about 50 g amounts of
the aniline. Other published synthetic routes proved to be
unsatisfactory. This reaction is not without hazard, since
significant amounts of HCN are generated as a gaseous
byproduct, partly or entirely by decomposition of the formed
isonitrosoacetanilide.16,17 The solid isonitrosoacetanilide was
F Journal of Medicinal Chemistry Onyeibor et al.
then heated with H2SO4, heating to temperatures no higher
than 70 °C. When this method was originally developed, H2-
SO4 then available was probably less concentrated that the
98% used now; the use of concentrated H2SO4 often leads to
the formation of byproducts including a black resin that is
difficult to filter. The most satisfactory results were obtained
with acid corresponding to the monohydrate; at lower concen-
trations ring closure to form isatins was poor. When the
reaction proceeded so as to give a good yield, the solution
usually became violet. The reaction mixture was quenched by
pouring onto ice when the crude isatin usually precipitated.
The isatin was purified by dissolving in aqueous NaOH and
adjusting the pH to neutrality when dark, resinous byproducts
usually separated. On acidification, the released substituted
isatinic acid eliminated a molecule of water on ring closure to
form the isatin, sometimes slowly.
Ortho-, meta-, and para-substituted anilines formed 7-, a
mixture of 4- and 6-, and 5-substituted isatins, respectively.
Mixtures of 4- and 6-substituted derivatives were separated18
by acidification of the sodium isatinate solution with acetic
acid, when the 4-substituted isatin was released (usually as
red needles). The mother liquors were acidified with HCl, when
the 6-substituted isatin was released, usually as yellow plates.
The reaction between some isatin precursors and H2SO4
resulted in a red solution instead of violet, and no isatin was
deposited on quenching with ice. Ether extraction of the
quenched reaction mixture extracted a small amount of
material, and by repeated extraction with ether and back-
extraction into a small volume of aqueous NaOH, a small
amount of the expected isatin was obtained on acidification.
The red ether-insoluble byproduct may have been an isatin
sulfonic acid.
General Method for Preparation of Halogenated Cryp-
tolepine Derivatives (11a-o). O,N-Acetylindoxyl (6a) (5 g,
23 mmol) for 11a-e and 11g-j, 5-bromo-O,N-acetylindoxyl
(6b) (6.84 g, 23 mmol) for 11k-n, or 6-chloro-O,N-acetylin-
doxyl (6c) (6.11 g, 23 mmol) for 11f and 11o and water (50
mL) were stirred under nitrogen at room temperature. A
solution of isatin (7a) or a derivative 7b-j (23 mmol) and KOH
(26 g, 0.46 M) in water (50 mL) was slowly added. The reaction
mixture was refluxed for 4 h and then cooled to 70 °C; air was
then bubbled through the liquid for 20 min. The mixture was
filtered, and the filtrate was acidified to pH 1 with concen-
trated HCl. The precipitate of quindoline-11-carboxylic acid
derivative 8a-o was collected, washed with water, dried, and
used for the next step without further purification. Decar-
boxylation was carried out by refluxing the latter product with
diphenyl ether (50 mL) for 6 h. After the mixture was cooled,
it was poured into petroleum ether (200 mL) and allowed to
stand overnight at 4 °C. The precipitate was collected, washed
with petroleum ether, and dried. The product, a quindoline
derivative 9a-o, was then dissolved in the minimum amount
of tetramethylenesulfone (5-10 mL), and an excess of io-
domethane (2-3 mL) was added. The reaction vessel was
sealed and heated with stirring at 60 °C overnight. When cool,
the reaction mixture was poured into ether (200 mL), and the
reaction vessel was washed with a little methanol; this was
then added to the ether that was allowed to stand overnight
at 4 °C. The precipitate of the cryptolepine derivative as the
hydroiodide salt 10a-o was collected and washed with ether
and then dissolved in a mixture of chloroform:methanol:NH4-
OH (35%), 90:10:1. The solution was filtered, washed with
water, dried over anhydrous Na2SO4, filtered again, and
evaporated to dryness under reduced pressure (40 °C). Puri-
fication was carried out by column-chromatographing the
product over silica gel G (60 íM, TLC grade), under positive
pressure eluting with chloroform containing increasing amounts
of methanol. Cryptolepine derivatives 10a-o were converted
to their hydrochloride salts 11a-o by adding HCl in methanol
(5%) and then crystallizing from chloroform/methanol or
chloroform/methanol/ethyl acetate.
1,2-Dichlorocryptolepine Hydrochloride (11a). The
title compound was prepared as above from 6a (23 mmol, 5.0
g) and 7b (23 mmol, 3.38 g). Yellow crystals, yield 10.9%. 1H
NMR of free base (CDCl3, ä): 4.70 (3H, s, NCH3), 7.02 (1H, t,
J ) 7.4 Hz, 7 or 8-H), 7.54 (1H, t, J ) 6.7 Hz, 7 or 8-H), 7.78
(1H, d, J ) 8.4 Hz, 6-H), 8.10 (1H, d, J ) 8.4 H, 9-H), 8.21
(2H, m, 3-H, 4-H), 8.61 (1H, s, 11-H). MS (EI, m/z, relative
intensity, %) 301 (25) [M+], 286 (71), 266 (52), 252 (100), 217
(25), 190 (12), 142 (52). Anal. (C16H10N2Cl2â1.5HCl) C, H, N.
2,3-Dichlorocryptolepine Hydrochloride (11c). The
title compound was prepared as above from 6a (23 mmol, 5.0
g) and 7c (23 mmol, 4.95 g). Yellow crystals, yield 1.1%. 1H
NMR of free base (CDCl3, ä): 4.80 (3H, s, NCH3), 7.05 (1H, t,
J ) 7.4 Hz, 7 or 8-H), 7.55 (1H, t, J ) 7.2 Hz, 7 or 8-H), 7.56-
8.11 (3H, m, 3Ar-H), 8.63 (1H, s, 1 or 4-H), 9.14 (1H, s, 11-H).
MS (EI, m/z, relative intensity, %) 301 (18) [M+], 288 (66), 286
(100), 252 (58), 216 (16), 188 (7), 142 (28). Anal. (C16H10N2-
Cl2âHCl) C, H, N.
3-Chlorocryptolepine Hydrochloride (11d). The title
compound was prepared as above from 6a (23 mmol, 5.0 g)
and 7d (23 mmol, 4.18 g). Yellow crystals, yield 8.51%. 1H
NMR of free base (CDCl3, ä): 4.70 (3H, s, NCH3), 6.97 (1H, t,
J ) 7.4 Hz, 7 or 8-H), 7.51 (1H, t, J ) 6.9 Hz, 7 or 8-H), 7.54
(1H, d, J ) 8.7 Hz, 6-H), 7.80 (1H, d, J ) 8.7 Hz, 9-H), 8.03
(1H, s, 4-H), 8.07 (1H, d, J ) 2.97 Hz, 1-H), 8.10 (1H, d, J )
3.5 Hz, 2-H), 8.70 (1H, s, 11-H). MS (EI, m/z, relative intensity,
%) 267 (100) [M+], 251 (35), 231 (8), 222 (8), 216 (12), 190 (4).
Anal. (C16H11N2ClâHCl) C, H, N.
4-Chlorocryptolepine Hydrochloride (11e). The title
compound was prepared as above from 6a (23 mmol, 5.0 g)
and 7f (23 mmol, 4.18 g). Yellow crystals, yield 4.1%. 1H NMR
of free base (CDCl3, ä): 4.80 (3H, s, NCH3), 7.05 (1H, t, J )
7.4 Hz, 7 or 8-H), 7.45 (1H, dd, 1-H), 7.55 (1H, t, J ) 6.9 Hz,
7 or 8-H), 7.85 (2H, m, 6-H, 9-H), 8.15 (2H, m, 2-H, 3-H), 8.80
(1H, s, 11-H). MS (EI, m/z, relative intensity, %) 266 (84) [M+],
252 (100), 232 (15), 216 (13), 190 (6), 126 (12), 108 (5). Anal.
(C16H11N2Clâ1.5HClâ2H2O) C, H, N.
8-Chlorocryptolepine Hydrochloride (11f). The title
compound was prepared as above from 6c (23 mmol, 6.11 g)
and 7a (23 mmol, 3.38 g). Yellow crystals, yield 15%. 1H NMR
of free base (CDCl3, ä): 4.80 (3H, s, NCH3), 7.01 (1H, dd, J )
2.0, 9.2, Hz, 1-H or 4-H), 7.60 (1H, t, J ) 7.9, 2-H or 3-H), 7.8
(1H, d, J ) 1.7 Hz, 9-H), 7.9 (1H dt, J ) 1.6, 6.7 Hz, 2-H or
3-H), 8.11 (1H, d, J ) 8.9, 1-H or 4-H), 8.13 (1H, d, J ) 8.7,
6-H), 8.19 (1H, dd J ) 1.7, 8.4, 7-H), 8.83 (1H, s, 11-H). MS
(EI, m/z, relative intensity, %) 267 (33) [M+], 266 (100) [M+],
251 (22), 250 (26), 216 (6), 133, (5). Anal. (C16H11N2Clâ1.5HCl)
C, H, N.
7-Bromo-2-chlorocryptolepine Hydrochloride (11k).
The title compound was prepared as above from 6b (23 mmol,
6.84 g) and 7b (23 mmol, 4.18 g). Yellow crystals, yield 13.0%.
1H NMR of free base (CDCl3, ä): 4.70 (3H, s, NCH3), 7.45 (1H,
d, J ) 9.2 Hz, 9-H), 7.54 (1H, d, J ) 8.9 Hz, 8-H), 7.72 (1H, d,
J ) 9.4, 4-H), 8.00 (1H, d, J ) 9.4 Hz, 3-H), 8.04 (1H, s, 1-H
or 6-H), 8.09 (1H, s, 1-H or 6-H), 8.50 (1H, s, 11-H). MS (EI,
m/z, relative intensity, %) 346 (100) [M+], 344 (64) [M+], 332
(80), 330 (62), 251 (18), 215 (15), 142 (15), 108 (10). Anal.
(C16H10N2BrClâHClâCHCl3) C, H, N.
7-Bromo-2-fluorocryptolepine Hydrochloride (11l). The
title compound was prepared as above from 6b (23 mmol, 6.84
g) and 7g (23 mmol, 3.80 g). Yellow crystals, yield 13.0%. 1H
NMR of free base (CDCl3, ä): 4.70 (3H, s, NCH3), 7.62 (2H,
m, 3-H, 4-H), 7.74 (1H, d, J ) 10, 9-H), 7.85 (1H, dd, J ) 2.8,
8.5 Hz, 1-H), 8.16 (1H, dd, J ) 4.3, 9.5, 8-H), 8.35 (1H, s, 6-H),
8.79 (1H, s, 11-H). MS (EI, m/z, relative intensity, %) 330 (37)
[M+], 328 (33) [M+], 316 (98), 314 (100), 235 (48), 208 (23),
158 (18), 118 (20). Anal. (C16H10N2BrFâHClâ2.5H2O) C, H, N.
7-Bromo-3-chlorocryptolepine Hydrochloride (11m).
The title compound was prepared as above from 6b (23 mmol,
6.84 g) and 7d (23 mmol, 4.18 g). Yellow crystals, yield 13.0%.
1H NMR of free base (CDCl3, ä): 4.71 (3H, s, NCH3), 7.55 (2H,
d, 8-H, 9-H), 7.70 (1H, d, J ) 8.9 Hz, 1-H), 8.10 (2H, m, 2-H,
4-H or 6-H), 8.30 (1H, s, 4-H or 6-H), 8.80 (1H, s, 11-H). MS
(EI, m/z, relative intensity, %) 346 (100) [M+], 344 (30) [M+],
332 (100), 330 (79), 251 (25), 216 (15), 142 (37), 108 (11). Anal.
(C16H10N2BrClâHClâ0.3C2H5COOCH3) C, H, N.
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7-Bromo-3-methylcryptolepine Hydrochloride (11n).
The title compound was prepared as above from 6b (23 mmol,
6.84 g) and 7j (23 mmol, 3.70 g). Brown crystals, yield 10.0%.
1H NMR of free base (CDCl3, ä): 2.72 (3H, s, 3-CH3), 4.70 (3H,
s, NCH3), 7.47 (1H, d, J ) 9.2, 1-H or 2-H), 7.48 (1H, d, J )
8.4 Hz, 9-H), 7.64 (1H, d, J ) 9.2 Hz, 1-H or 2-H), 7.88 (1H, s,
4-H), 8.02 (1H, d, J ) 8.4 Hz, 8-H), 8.23 (1H, s, 6-H), 8.78 (1H,
s, 11-H). MS (EI, m/z, relative intensity, %) 326, 324 (100) [M+],
311, 309 (26), 229 (7), 230 (5). Anal. (C17H13N2Brâ1.6HCl) C,
N; H: calcd, 3.81; found 4.31.
2,8-Dichlorocryptolepine Hydrochloride (11o). The
title compound was prepared as above from 6c (23 mmol, 6.11
g) and 7b (23 mmol, 4.18 g). Yellow crystals, yield 15%. 1H
NMR of free base (CDCl3, ä): 4.76 (3H, s, NCH3), 6.98 (1H,
dd, J ) 1.9, 9.0 Hz, 3-H or 7-H), 7.70 (1H, d, J ) 2.2 Hz, 1-H
or 9-H), 7.74 (1H, dd, J ) 2.5, 6.9 Hz, 3-H or 7-H), 8.50 (2H,
d, J ) 9.7 Hz, 4-H and 6-H), 8.10 (1H, d, J ) 2.5 Hz, 1-H or 9-
H), 8.70 (1H, s, 11-H). MS (EI, m/z, relative intensity, %) 301
(100) [M+], 286 (13), 284 (20), 264 (6), 215 (4), 150 (5), 123 (7).
Anal. (C16H10N2Cl2â1.4HCl) C, H, N.
2-Bromo-7-nitrocryptolepine Hydrochloride (13). Com-
pound 12 (1 g, 2.88 mmol) was dissolved in 40 mL of nitric
acid (69%):glacial acetic acid (1:1) and stirred at room tem-
perature for 24 h. The reaction mixture was cooled on ice,
basified with strong sodium hydroxide solution, and filtered.
The dried product was column-chromatographed and converted
to the hydrochloride salt as above. Yellow crystals, yield 13.0%.
1H NMR, (CF3COOD, ä): 4.93 (3H, s, NCH3), 8.06 (1H, d, J )
8.1 Hz, 9-H), 8.38 (1H, d, J ) 10.8 Hz, 4-H), 8.46 (1H, d, J )
10.8, 3-H), 8.64 (1H, s, 1-H), 8.90 (1H, d, J ) 8.1 Hz, 8-H) 9.16
(1H, s, 11-H), 9.71 (1H, s, 6-H). MS (EI, m/z, relative intensity,
%) 357, 355 (100) [M+], 342, 340 (12), 327, 325 (20), 311, 309
(35), 230 (54), 229 (48), 158 (18), 118 (20). Anal. (C16H10N3O2-
BrâHCl) H, N; C: calcd, 48.9; found 51.2.
Antiplasmodial Assay. P. falciparum strain K1 was kindly
supplied by Professor D. C. Warhurst (London School of
Hygiene and Tropical Medicine). Malaria parasites were
maintained in human A+ erythrocytes suspended in RPMI
1640 medium supplemented with A+ serum and D-glucose
according to the methods of Trager and Jensen (1976)19 and
Fairlamb et al. (1985).20 Cultures containing predominantly
early ring stages were used for testing. Compounds were
dissolved or micronized in DMSO and further diluted with
RPMI 1640 medium (the final DMSO concentration did not
exceed 0.5% which did not affect parasite growth). Two-fold
serial dilutions were made in 96-well microtiter plates in
duplicate, and infected erythrocytes were added to give a final
volume of 100 íL with 2.5% hematocrit and 1% parasitemia.
Chloroquine diphosphate was used as a positive control, and
uninfected and infected erythrocytes without compounds were
included in each test. Plates were placed into a modular
incubator gassed with 93% nitrogen, 3% oxygen, and 4%
carbon dioxide and incubated at 37 °C for 48 h. Parasite growth
was assessed by measuring lactate dehydrogenase activity as
described by Makler et al., 1993.21 The reagent used contained
the following in each mL acetylpyridine adenine dinucleotide
(APAD), 0.74 mg; lithium lactate, 19.2 mg; diaphorase, 0.1 mg;
Triton X-100, 2 íL; nitroblue tetrazolium, 1 mg; and phenazine
ethosulfate, 0.5 mg. Fifty microliters of this reagent was added
to each well and mixed, and plates were incubated for 15 min
at 37 °C. Optical densities were read at 550 nm using a
Dynatech Laboratories MRX microplate reader, and percent
inhibition of growth was calculated by comparison with control
values. IC50 values were determined using linear regression
analysis (Microsoft Excel). A minimum of three separate
determinations was carried out for each compound.
In Vivo Antimalarial Test. This was carried out using
Peters’s 4-day suppressive test against P. berghei infection in
mice.11 Female BALB/C mice, weight 18-20 g, were inoculated
with P. berghei (ANKA); each mouse received 1  107 infected
erythrocytes by iv injection. Drugs were administered by ip
injection in 0.2 mL of inoculum daily for four consecutive days.
Control and test groups all contained five mice. On day 5 of
the test a blood smear was taken, and the animals were killed.
The percent suppression of parasitemia was calculated for each
dose level by comparing the parasitemias present in infected
controls with those of test animals; survival times were
recorded, taken as the number of days before the animals
showed signs of illness due to malaria. Chloroquine diphos-
phate was used as a positive control.
Cytotoxicity Assay. MAC15A (murine adenocarcinoma of
the colon) cells were available in our laboratory. Cells were
routinely maintained as monolayer cultures in RPMI1640
culture medium supplemented with foetal calf serum (10%),
sodium pyruvate (1 mM), L-glutamine (2 mM), and penicillin/
streptomycin (50 IU mL-1/50 íg mL-1, and buffered with
HEPES (25 mM). Chemosensitivity was assessed using the
MTT assay.22 Briefly, 2  103 cells were inoculated into each
well of a 96-well plate and incubated overnight at 37 °C in an
humidified atmosphere containing 5% CO2. All drugs were
dissolved in DMSO and then diluted in culture medium to give
a broad range of concentrations; the maximum DMSO con-
centration in any well was 0.1% shown not to affect cell growth.
Medium was removed from each well and replaced with drug
solutions (eight wells per drug concentration), and the plates
were then incubated for a further 96 h before cell survival was
determined. Culture medium was replaced with fresh medium
(180 íL) prior to the addition of 20 íL of MTT solution (0.5
mg mL-1). Following 24 h incubation at 37 °C, medium plus
MTT was removed from each well and the formazan crystals
were dissolved in DMSO (150 íL/well). Absorbances of the
resulting solutions were read at 550 nm and cell survival was
calculated as the absorbance of treated cells divided by the
control (RPMI medium plus 0.1% DMSO). Results were
expressed in terms of the IC50 values (i.e. concentration of drug
required to kill 50% cells), and all experiments were performed
in triplicate.
Determination of pKa Values. Acid dissociation constants
were determined spectrophotometrically using a Hewlett-
Packard HP8451A diode-array UV spectrophotometer. UV
spectra of each compound (0.05 mg mL-1) dissolved in buffers
of varying pH values ranging from 5.8 to 13.0 as well as in
0.1 M NaOH and 0.1 M HCl to ensure that the maximum and
minimum absorbances of the main peak (ìmax) were deter-
mined. A minimum of seven buffer solutions was used for each
compound. For buffers of pH 5.8-8.0 Clark and Lub’s phos-
phate buffer (KH2PO4/NaOH) 0.1 M was used and for pH 8.4-
13.0 Sorensen’s glycine I buffer 0.1 M was employed.23 From
a plot of pH against the absorbance of ìmax, the pH correspond-
ing to the midpoint between the maximum and minimum
absorbance of ìmax (pKa value) was determined. Two separate
experiments were carried out for each compound.
Determination of Inhibition of â-Hematin Formation.
The quantitative BHIA (â-hematin inhibitory activity) assay
is based on the differential solubility of hemin and â-hematin
in DMSO and NaOH solution, respectively.24 The method
determines a 50% inhibitory concentration for â-hematin
inhibition in equivalents of the compound under test with
respect to hemin (BHIA50). A total of 50 íL of an 8 mM solution
of hemin was dissolved in DMSO and distributed into 96-well
U-bottom microplates (0.4 ímol/well); 50 íL of different
compounds in water, in doses from 0.25 to 2 (or 4 if they were
soluble) molar equivalents to hemin, were added to triplicate
test wells. In control wells, 50 íL of water was added. Water-
insoluble compounds were solubilized in 25 íL of DMSO and
then added to hemin prepared at 16 mM and distributed into
the wells in 25 íL aliquots. The final concentration of DMSO/
well was kept constant at 25%. â-Hematin formation was
initiated by the addition of 100 íL of 8 M acetate buffer (pH
5.0), and the plates were then incubated at 37 °C for 18 h.
Following centrifugation to isolate DMSO-insoluble â-hematin,
the product was dissolved in 0.1 M NaOH solution and
determined spectrophotometrically at 405 nm as previously
described.24,15
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